Director, Drug Delivery
Halozyme Therapeutics
San Diego, California, United States
David Kang heads the Drug Delivery Research team at Halozyme Therapeutics, and is a subject matter expert in recombinant human hyaluronidase facilitated rapid, high-volume subcutaneous administration of biotherapeutics. Prior to that, David spent over a decade between Pfizer and Schering-Plough researching oncology therapeutics and viral based gene delivery. He started his research career at the University of California at San Diego working on gene therapy approaches on infectious disease, where we also did his undergraduate studies in microbiology and graduate studies in virology.
Disclosure information not submitted.
Biologics Summit Part II Morning Session
Monday, July 8, 2024
9:00 AM – 12:00 PM CET
Biologics Summit Part II Afternoon Session
Monday, July 8, 2024
1:00 PM – 2:30 PM CET
Workshop: Debunking the Myths of Subcutaneous Drug Delivery
Monday, July 8, 2024
1:00 PM – 5:00 PM CET
Friday, July 12, 2024
8:00 AM – 10:00 AM CET